Melya Hughes Crameri
Managing Director at Awen Life Sciences
United Kingdom
Overview
Work Experience
Managing Director
2010 - Current
Board of Directors · Entrepreneurship · Corporate Development · Strategy · Leadership
Partner
2015 - 2023
Ventac Partners work to advance healthcare and biotechnology innovations and create the maximum value for inventors and investors.
Non Executive Director
2017 - 2019
LSHW is a company limited by guarantee and a wholly-owned subsidiary of the Welsh Government, supporting engagement from the public and private sector to develop opportunities for improved health and wellbeing.
Founder & CEO
2011 - 2013
Caltherix Inc. - microprotein therapeutics addressing GPCRs and ion channel targets in pain and oncology
Chief Executive Officer (US) and Executive Management (CH)
2005 - 2010
President & CEO, Genetic Chemistry Inc. (Evolva US) (May 2008- June 2010) Founder, Genetic Chemistry Inc. (Evolva US) (April 2007- April 2008) VP Alliances & IP, Evolva SA (March 2005 - April 2008) Evolva/Genetic Chemistry Inc. was focused on synthetic biology approaches to discover and develop small molecule therapeutics (anti-infectives).
Business & IP Strategy Consultant
2004 - 2005
Head of Licensing & Patents
1999 - 2003
The FMI (Novartis Research Foundation) is a center for biomedical research with about 20 research groups and over 250 staff, with focus areas including oncology, metabolic disease, neurosciences, epigenetics and agribusiness.
Patent Counsel
1998 - 1999
Geron focused on stem cell therapies and inhibition of telomerase (oncology).
Geron is a biotechnology company that specializes in developing blood cancer treatments for hematologic malignancies.
Raised $999,543,965.00 from Pharmakon Advisors and Hercules Capital.
Patent Agent
1993 - 1998
Research Scientist
1990 - 1992
Merck is a biopharmaceutical company that offers medicines and vaccines for various diseases.
Raised $5,586,000.00 from Private Capital Advisors.